Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of B-cells and autoantibodies after low-dose methotrexate.

Ingrid Böhm1

  • 1Department of Radiology (Formerly Department of Dermatology), University of Bonn, Sigmund-Freud Strasse 25, 53105, Bonn, Germany. i.boehm@uni-bonn.de

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|September 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What looks like a contrast reaction may not be a contrast reaction.

European journal of radiology·2025
Same author

Technical and clinical reasons for negative skin test results following intradermal testing of contrast media.

European journal of radiology·2025
Same author

Immunological Activity of Peripheral Blood Lymphocytes Points to Lupus-Related Cause of Stroke in Lupus Erythematosus.

Annals of vascular surgery·2021
Same author

Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity.

Allergy·2020
Same author

Esthetic aspect of radiology.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2019
Same author

Use of GBCA in MRIs for High-Risk Patients.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS·2019

Low-dose methotrexate (MTX) effectively improved lupus erythematosus (LE) symptoms by reducing B-cells and autoantibodies, particularly with long-term use. This treatment did not cause general immunosuppression in patients.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Lupus erythematosus (LE) is an autoimmune disease requiring effective treatment.
  • Patients refractory to standard therapies (antimalarials, glucocorticosteroids) need alternative options.
  • Understanding methotrexate's (MTX) immunomodulatory effects in LE is crucial.

Purpose of the Study:

  • To evaluate the efficacy of low-dose methotrexate (MTX) on immunological markers in lupus erythematosus (LE) patients.
  • To compare the short-term (10 weeks) effects of MTX.
  • To correlate immunological changes with clinical outcomes in LE patients.

Main Methods:

  • Retrospective analysis of 22 LE patients treated with 10-30 mg MTX weekly.
  • Analysis of serum autoantibodies and peripheral blood lymphocyte subsets via flow cytometry.

Related Experiment Videos

  • Assessment of clinical response and immunological parameter changes over time.

    • Main Results:

    • Clinical improvement observed in 21/22 patients (68.2% complete response).
    • Significant reduction in absolute B-cell counts after long-term MTX treatment (P = 0.00254).
    • Long-term MTX associated with autoantibody down-regulation, more pronounced in patients with pre-existing autoantibodies.

    Conclusions:

    • Low-dose MTX demonstrates significant clinical efficacy in refractory LE patients.
    • Long-term MTX treatment modulates B-cell populations and autoantibody levels.
    • MTX's distinct short- and long-term immunologic effects contribute to clinical improvement without causing immunosuppression.